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A multidisciplinary team of experts on active surveillance for prostate cancer defined a set of 
health-related quality-of-life outcomes and measures to be used to design future studies. Such 
studies will eventually provide information to guide treatment decision-making and more closely 
address patient well being. 
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Abstract 
Background: Literature on the health-related quality of life (HRQoL) for men with localized 
prostate cancer (PCa) on active surveillance (AS) shows a need for methodological guidance 
regarding HRQoL issues and how to address them. 
Objective: The European School of Oncology Task Force (ESO TF) aimed to identify a core 
set of research questions and related measures to include in AS HRQoL studies. 
Design, setting, and participants: A modified Delphi study was used to reach consensus on 
AS HRQoL research topics and tools between 2014 and 2015. Data were collected by 
engaging a multidisciplinary team of 15 experts. 
Outcome measurements and statistical analysis: An open-ended questionnaire was used to 
collect information from ESO TF members regarding issues in AS HRQoL research. Then a 
structured questionnaire was used to collect ratings on the usefulness/importance of different 
AS HRQoL aspects. Items that 80% of ESO TF members rated as useful/important were 
retained. Items with a 50–80% rating were discussed to reach final agreement. 
Results and limitations: Six main research questions concerning the selection of outcome 
measures, measurement tools, and comparison groups were identified as relevant. The core 
*Manuscript
set of measures identified were related to individual characteristics, psychological 
dimensions; decision-making–related issues, and physical functioning. The multidisciplinary 
expertise of ESO TF members was a significant asset, but bringing different backgrounds to 
the discussion table represented a challenge. 
Conclusions: HRQoL measures have to be sensitive to the specific needs of men on AS. The 
definition of HRQoL outcomes will enhance a broader understanding of the HRQoL of men 
on AS and sustain patient-centered medicine. 
Patient summary: An international panel agreed on a set of health-related quality-of-life 
aspects to be assessed among men on active surveillance for prostate cancer. Valid relevant 
questionnaires were identified. The experts’ indications lay a foundation for future research 
and clinical practice. 
 
 
1. Introduction 
With international guidelines recommending that active surveillance (AS) should be offered 
to men with very low-risk/low-risk prostate cancer (PCa) when appropriate, and patients’ 
associations stressing the need to be offered all available options, there has been slow but 
steady implementation of AS [1,2]. 
AS reduces the burden of treatment-related side effects, but men may live with greater 
uncertainty because of the possibility of future reclassification of their cancer [3]. There is 
still concern about the possible impact of living with untreated PCa on health-related quality 
of life (HRQoL). Currently available studies do not allow firm conclusions, mainly because 
of methodological flaws such as lack of comparison group(s), no randomization, and limited 
follow-up [4,5]. 
To address such limitations and to provide directions for future AS HRQoL studies, the 
European School of Oncology (ESO) established an international task force (TF) to address 
the main issues regarding assessment of AS HRQoL from a multidisciplinary and 
multiprofessional perspective. This article presents the recommendations of the ESO TF on a 
core set of HRQoL factors that should be considered for men on AS. Study design criteria are 
outlined and specific validated questionnaires are described. 
 
2. Materials and methods 
A modified Delphi approach was used to establish recommendations for assessment of AS 
HRQoL. Consensus was achieved after the following six steps (Fig. 1). 
(1) Kick-off meeting: A multidisciplinary group of 15 AS experts joined a discussion on AS-
related HRQoL issues. The panel included urologists, radiation oncologists, 
psychologists, a health scientist, a data scientist, project coordinators, epidemiologists, 
and advocacy group (Europa Uomo) representatives. A group coordinator (L.B.) and a 
core working group (F.K., T.R., L.V., S.V.) were nominated. 
(2) Systematic literature exploration: A background search was conducted to obtain an 
overview of the methodology used to conduct research on HRQoL among men on AS. A 
related systematic review was published in 2015 [4]. 
(3) Round 1: An open-ended questionnaire was mailed for first collection of suggestions 
regarding what aspects measurement of HRQoL for men on AS should include and how it 
should be conducted. Two versions were used: (1) one for researchers already conducting 
AS HRQoL assessment and (2) one for ESO TF members not directly involved in 
research, such as patient association members and some clinicians. The group coordinator 
reviewed and summarized the responses. 
(4) Round 2: In the second round, ESO TF members were asked to rate the usefulness or 
importance of aspects concerning AS HRQoL measurement (outcome measures, 
measurement tools, control groups, and timing of assessment) derived from round 1. A 
survey of 63 items using a 4-point Likert scale (from “not useful” to “very useful”) was 
developed. Data collection was anonymous. Twelve out of 15 (80%) TF members 
returned the opinion survey. Items rated useful and/or important for inclusion in AS 
HRQoL assessment by <50% of respondents were excluded; items rated useful and/or 
important by 80–100% of respondents were included as recommendations; items rated as 
useful and/or important by 50–80% of respondents were considered as topics for further 
discussion. During this round, agreement about inclusion or exclusion was reached for 
25/63 items (21 items included, 4 excluded). These thresholds were specified a priori. 
Agreement at 80–100% is related to agreement at a level of qualified majority. 
Agreement at a level of absolute but not qualified majority led to further discussion in the 
face-to-face meeting. 
(5) Round 3: Experts participated in a face-to face meeting in Madrid during the European 
Association of Urology annual meeting to discuss the aspects of AS-related HRQoL 
assessment that had reached an agreement level of 50–80% (38 items); 13/15 of the TF 
members attended this meeting. The issues mainly discussed were the types of 
questionnaire to use on the basis of their validity and generalizability, and on avoiding 
patient burden in completing them. A further topic of discussion was the importance of 
identifying research questions that also had clinical implications in the sense of support 
for patients in the decision-making process on whether or not to opt for AS. 
(6) Round 4: Decisions on selected methodological issues that were not resolved from round 
3 were left to the core working group given their expertise with the specific HRQoL 
measurement tools. 
 
3. Results 
A core set of AS HRQoL outcomes resulted from the consensus process, together with 
adequate standardized measurement tools to evaluate such outcomes (Table 1). Suggestions 
regarding assessment timing were also provided (Fig. 2). 
 
3.1. How to measure HRQoL for men on AS 
HRQoL ranges from the individual perception of health status and ability to function in life to 
subjective evaluation of the extent to which physical, emotional, and social well being may 
be affected by a medical condition or its treatment [6]. 
Since disease-specific and generic HRQoL areas may influence each other in PCa, the ESO 
TF suggested a broad evaluation. It was agreed (83%) to use the Short Form 36 (SF-36) 
questionnaire or the abbreviated 12-item version (SF-12) [7,8] to measure generic HRQoL. In 
addition, use of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) 
questionnaire was suggested as a PCa-specific tool [9]. 
 
3.2. Association of patient characteristics with AS HRQoL 
Understanding how individual features may impact acceptance and adherence to AS could 
support clinicians and patients to reach a shared decision. TF members (>80%) agreed that 
demographic characteristics (age, marital status, education, working status), comorbidities, 
and personality traits should be assessed. 
It has been found that age, marital status, and education are predictors of HRQoL among men 
on AS [10]. In fact, younger men on AS may be more anxious about missing the window of 
opportunity for radical curative treatment. The presence of a partner or spouse may offer 
support to men, but may also trigger the decision to switch to a radical treatment. The ESO 
TF group suggested that the view of partners should be sought when proposing AS to 
facilitate a shared decision. Level of education should be considered because the assumption 
that men with higher levels of education can more effectively process AS-related medical 
information is widespread, but still not supported by evidence. 
Comorbidities should be recorded as a potential confounding variable for HRQoL, via either 
validated questionnaires (eg, the Self-administered Comorbidity Questionnaire [11]) or ad 
hoc interviews. 
Personality characteristics are associated with PCa-related coping, HRQoL, and decisional 
regret [11]. TF members agreed (90%) to consider personality as a factor that may impact 
AS-related HRQoL. The decision for the assessment tool was left to the core group, who 
recommended use of the abbreviated form of the Revised Eysenk Personality Questionnaire 
[12]. 
 
3.3. Effect of psychological dimensions on HRQoL among AS patients 
Anxiety and depression as indicators of psychological burden as well as coping with cancer 
were rated as the most important psychological dimensions to address in AS HRQoL studies. 
 
3.3.1. Anxiety 
Anxiety as a result of living with untreated PCa may represent a significant problem. The 
majority of men who opted for AS reported low levels of anxiety in the short term [4]. 
Reported rates of anxiety above a clinical threshold show large variation, ranging from 1–2% 
[13] to 23% [14]. Men with heightened anxiety are more likely to switch to radical treatment 
in the absence of medical reasons [15–17]. 
The TF (92%) included anxiety as an important factor in AS-related HRQoL. For assessment 
of both generic and disease-specific anxiety, the State Trait Anxiety Inventory (STAI) and the 
Memorial Anxiety Scale for Prostate Cancer (MAX-PC) were recommended. The STAI 
differentiates between a temporary condition of state anxiety and a more general and 
longstanding dimension of trait anxiety [18]. The MAX-PC provides a brief and effective 
measure of anxiety specifically related to PCa [19]. 
 
3.3.2. Depression 
The body of literature on depression among cancer patients has increased exponentially, but 
very few studies have addressed depression among men on AS. In these studies, scores for 
men on AS were low [4] and did not change over time [17]. Owing to its huge impact on 
HRQoL, the ESO TF recommended (80%) measurement of depression. So far, studies on AS 
have used the Center for Epidemiological Studies Depression Scale, the Hospital Anxiety and 
Depression Scale, and the nine-item depression scale of the Patient Health Questionnaire 
(PHQ-9). The core group considered the two-item short version of the PHQ as the most user-
friendly for an initial screening [20]. 
 
3.3.3. Coping with AS 
Coping strategies may have an important impact on HRQoL during cancer management. So 
far, only one study has addressed the role of coping in AS [4]. The TF (100%) agreed on 
considering coping with cancer as an influential factor and recommended the Mini-Mental 
Adjustment to Cancer scale [21]. 
 
3.4. Decision-making between AS and curative treatments 
One of the factors that may influence HRQoL of men on AS is how they choose between 
radical treatment and AS [11]. When men were asked which were the most important 
advantages of AS, the predominant answers were related to delaying the side effects of 
radical therapies [22,23]. Disadvantages reported were the risk of unfavorable consequences 
(eg, progression and metastases) and the distress associated with that risk. The TF members 
recommended addressing the reasons for choosing (83%) or not choosing AS (91%) to 
facilitate a shared decision. 
Uncertainty about which action to take can be a psychological stressor, and addressing the 
potential conflict in the decision-making process may be of great value in clinical practice. 
However, the TF did not unanimously agree (70%) on recommending inclusion of 
assessment of decisional conflict (DC) in the core outcome set. Given that higher DC is 
associated with lower patient adherence to and satisfaction with the choice, discussion among 
core group experts resulted in a suggestion to include evaluation of DC as a factor potentially 
influencing HRQoL. The validated Decisional Conflict Scale [24] was recommended for DC 
assessment. 
Since DC may lead to a sense of regret in the post-treatment phase, the TF agreed (83%) on 
evaluating this issue. The Decision Regret Scale, a validated tool available for this purpose 
[25], was recommended by the core group. 
The TF agreed on investigation of family and social support (90% agreement) given their 
influence on decision-making and HRQoL [11]. The final recommendation by the core group 
was to adopt the Social Wellbeing Scale of the FACT-P or a more specific tool such as the 
Multidimensional Scale of Perceived Social Support to assess an individual’s perception of 
social support [26]. 
Since 20% of patients on average choose to stop AS in the absence of a clinical 
recommendation but because of anxiety or personal choice [27], TF members suggested 
(100%) collection of the individual reasons underlying these cases. This information may be 
useful in addressing the causes, such as possible cancer-related anxiety, to improve future 
retention rates. 
 
3.5. Physical functioning 
Even in the absence of PCa-related symptoms, assessment of different physical functional 
issues, such as urinary and erectile functions, is recommended (91%) because they could be 
impaired in relation to age and invasive procedures used for PCa monitoring (ie, repeated 
biopsies) [28]. No unanimous agreement (50–80%) was reached regarding any of the 
measurement tools available: the Sexual Health Inventory for Men (SHIM), the 5-item 
version of the International Index of Erectile Function (IIEF-5), the Expanded Prostate 
Cancer Index Composite (EPIC), and the International Prostate Symptom Score (IPSS). The 
core working group suggested use of the IPSS [29], which evaluates urinary symptoms 
specifically related to the prostate, and IIEF-5 [30], which was preferred to SHIM since a 
greater percentage of the TF members were familiar with it (81% for IIEF-5 vs 50% for 
SHIM). EPIC was indicated as a second choice because it focuses more on treatment side 
effects rather than on impairment of normal functioning. 
 
3.6. Clinically relevant cohorts for comparison of HRQoL for men with localized PCa in 
AS 
Up to now, studies have compared HRQoL outcomes for men on AS with the general male 
population and those who have undergone radical treatment [5]. 
The TF identified three cohorts of interest for comparison with men on AS: 
(1) Men with a PCa diagnosis who were eligible for AS but chose radical treatment to 
minimize the hazard of progression (100% consensus). 
(2) Men who have undergone minimal invasive focal therapy (attentively identified), which 
entails the risk of a misclassified disease at diagnosis (92% consensus). 
(3) Men who chose AS but were later advised to quit AS owing to disease reclassification or 
progression and received radical treatment (83% consensus). 
 
4. Discussion 
The ESO TF experts contributed with their different expertise to the definition of a core set of 
research issues that need to be addressed when evaluating HRQoL among men with PCa on 
AS. Men with low-risk indolent PCa who choose AS face the peculiar challenge of being 
diagnosed with cancer and not immediately (potentially never) being treated for their disease. 
Therefore, assessment of HRQoL has to be tailored to this specific population. For this 
reason, it is important to identify specific outcomes and to measure them using validated 
tools. 
The main results of the consensus are that: (1) fundamental aspects of AS HRQoL deal with 
overall self-perception of well being, professional and physical functioning, and family role; 
(2) anxiety and depression represent the two main psychological consequences of cancer 
diagnosis and recurrence, and thus need to be taken into account; and (3) the patient decision-
making process between active treatment and observational strategies has to be clear to both 
the patient and clinician, because this information may support men in coming to a decision 
that is satisfactory in the short and long run. 
Implementation of the recommendations presented in this paper will allow consistent data 
collection. Researchers could choose, among the suggestions, which AS HRQoL issues to 
address while taking into account the feasibility and time required for an average patient to 
complete the related questionnaires. A preliminary overall cost-effectiveness evaluation 
should be conducted and should take into account how much information the study adds to 
what has already been properly investigated. Moreover, researchers will need to identify 
which tools are validated in the patient’s native language. 
A preliminary trial should also be conducted to assess the cognitive, emotional, and time 
burdens for patients when completing the questionnaires. Comparison of results from 
different populations across the world will become feasible, and could eventually lead to a 
better and broader understanding of the HRQoL of men on AS. 
The different knowledge and expertise that ESO TF members brought to the table represented 
an incredible asset throughout the consensus process. Nonetheless, these differences led to 
some difficulties. In particular, differences in familiarity with the assessment tools between 
clinicians and research psychologists required thorough discussion before reaching 
agreement. Sharing the common aim of addressing HRQoL issues in AS from both a clinical 
and a research point of view, all the ESO TF members made an effort to go beyond the 
boundaries of their specialty field and their comfort zone, which provides an important 
example of a multidisciplinary approach. Establishment of the TF and the work conducted to 
achieve its aim represent an approach that should be implemented when designing research 
on AS HRQoL: collaborative, open-minded, evidence-based, thought-provoking research. It 
is reasonable to think that more work is still required to address the limitations of the findings 
reached by the TF. It is desirable to continue such collaborative work and determine the 
opportunity to discuss with other clinicians and researchers all over the world who are expert 
in AS, and in the assessment of QoL, what emerged from the TF. 
 
5. Conclusions 
This work offers conceptual and methodological suggestions that could be useful in both 
research and clinical practice for men diagnosed with PCa. Implementation of these 
suggestions in different cultures will allow the uro-oncologic community to gain a better 
understanding of how men face living with an untreated cancer and to design assessment and 
ad hoc counseling interventions to support AS-eligible men and their families. 
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Fig. 1 – Taskforce flowchart. AS = active surveillance; HRQoL = health-related quality 
of life. 
 
Fig. 2 – Suggested timeline for data collection. 
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Kick-off meeting
 
· To achieve consensus on the creation of the task-
force (TF).
• To identify the TF goals.
• To create a core working group.
Systematic literature review
 
To have a picture of methods used to conduct research on 
HRQoL in men on AS. 
An open-ended questionnaire was mailed to conduct a ﬁrst 
collection of information and suggestions regarding what 
and how the measurement of HQoL of men on AS should 
be addressed. 
Round 1
Experts were asked to rate the usefulness and importance of 
aspects concerning measurement of HRQoL in AS 
(outcome measures, measurement tools, control groups and 
time points assessment) derived from round 1. 
Round 2
Experts participated in a face-to face meeting in Madrid 
during EAU annual meeting to discuss the issues on which 
no consensus was achieved in the second round.
Round 3
Analysis
Analysis
Decisions on selected methodological issues that remained 
indeterminate from round three were left to the core 
working group who was familiar with the speciﬁc 
measurement tools. 
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Entrance on AS After 1st  yr 
re-biopsy 
Each yr following 
1st re-biopsy 
After radical 
treatment following 
exit from AS 
3 yrs after radical 
treatment 
Patient-related characteristics 
Decision making-related factors (i.e., Reasons for not choosing AS, Reasons for choosing AS, 
Partners’ preferences, Decisional Conflict, °Social support, *Decisional Regret) 
Psychological dimensions (i.e., Anxiety, Coping, Depression) 
Health-related Quality of Life 
Physical functioning (i.e., Erectile function, Urinary function) 
°	*	°	  °	 °	
Table 1 – Summary of the research questions identified as relevant to consider when 
tracking health-related quality of life among men with prostate cancer on active 
surveillance (AS) and the final core set of factors and measures prioritized by the Delphi 
panel 
Research question Features Suggested tool 
1. Health-related quality of life  SF-12/SF-36 
  FACT-P 
2. Patient-related characteristics Age Interview 
 Education Interview 
 Marital status Interview 
 Employment status Interview 
 Comorbidities SCQ/interview 
 Personality EPQ-R 
3. Psychological dimensions Generic anxiety STAI 
 PCa-specific anxiety MAX-PC 
 Coping Mini-MAC 
 Depression PHQ-2 
4. Decision-making–related process Reasons for not choosing AS Interview 
 Reasons for choosing AS Interview 
 Reason for stopping AS Interview 
 Decision conflict Decisional Conflict Scale 
 Partners’ preferences Interview 
 Social support Social Wellbeing Scale 
(FACT-P), MSPSS 
 Regret Decisional Regret Scale 
5. Physical functioning Erectile function IIEF 
 Urinary function IPSS 
6. Comparison group Men with PCa diagnosis eligible for AS but 
chose radical treatment (RP, ERT, BT) 
 
 Men who underwent focal therapy  
 Men who chose AS but were later advised to 
quit AS owing to disease reclassification or 
progression and received radical treatment 
 
BT = brachytherapy; EPQ = Eysenk personality scale; ERT = external radiation therapy; 
FACT-P = Functional Assessment of Cancer Therapy-Prostate; IIEF = International Index of 
Erectile Function; IPSS = International Prostate Symptom Score; MAX-PC=Memorial 
Anxiety Scale for Prostate Cancer; Mini-MAC = Mini-Mental Adjustment to Cancer; MSPSS 
= Multidimensional Scale of Perceived Social Support; PCa = prostate cancer; PHQ-2 = 
Patient Health Questionnaire-2; RP = radical prostatectomy; SCQ = Self-administered 
Comorbidity Questionnaire; SF-36/12 = Short Form 36/12; STAI = State Trait Anxiety 
Inventory. 
 
Table
